Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EyePoint, Inc.PSDV · Entity 5702 | EVP, Corp. & Comm'l Dev. | June 27, 2017 | June 29, 2017 |
| Orexigen Therapeutics, Inc.OREX · Entity 157016 | Director | July 14, 2017 | July 18, 2017 |
| VIVEVE MEDICAL, INC.VIVE · Entity 11899 | Director | January 03, 2023 | January 05, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EyePoint, Inc.
Report date June 27, 2017 · Filed June 29, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 45,000 |
Reported balance
After 2017-06-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-27 · Grant · Acquired 45,000 · Balance 45,000 F1: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.77 · Expires 2027-06-27 | Direct | 90,000 |
Reported balance
After 2017-06-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-27 · Grant · Acquired 90,000 · Balance 90,000 F3: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
F2: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date.
F3: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018.
Orexigen Therapeutics, Inc.
Report date July 14, 2017 · Filed July 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.88 · Expires 2027-07-13 | Direct | 5,000 |
Reported balance
After 2017-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-14 · Grant · Acquired 5,000 · Balance 5,000 F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer.
VIVEVE MEDICAL, INC.
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 36,000 |
Reported balance
After 2023-01-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-01-03 · Grant · Acquired 36,000 · Balance 36,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock.
F2: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2023 Filed Jan 5, 2023 16:03 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantRestricted Stock Unit · Derivative | 36,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-000483 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. F2 · derivative.expiration_date: The RSUs vest in full on the earlier of December 1, 2023 or the closing of a Sale Event (as defined in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan), subject to the reporting person's continuous service to the Issuer. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 16:04 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 22,000 | $0.00 Strike: $1.26 | $0.00 |
DisclosureSEC source: 0001437749-22-000548 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2032-01-03 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan, as amended (the "2013 Plan") and received 22,000 non-qualified stock options on January 4, 2022 (the "Grant Date"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date. Read SEC document |
| June 23, 2021 Filed Jun 25, 2021 16:06 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 51,700 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001437749-21-015658 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2031-06-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 51,700 non-qualified stock options on June 23, 2021 (the "Grant Date"). The non-qualified stock options shall vest and become exercisable in 48 equal monthly installments from the Grant Date. Read SEC document |
| January 20, 2021 Filed Jan 22, 2021 19:17 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-001112 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 25,000 RSUs on January 20, 2021 (the "Grant Date"). The RSUs vest in full on the second anniversary of the Grant Date. F2 · derivative.expiration_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 25,000 RSUs on January 20, 2021 (the "Grant Date"). The RSUs vest in full on the second anniversary of the Grant Date. Read SEC document |
| September 21, 2020 Filed Sep 22, 2020 11:03 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 165,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001437749-20-019985 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2030-09-20 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 165,000 non-qualified stock options on September 21, 2020 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 19:30 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 330,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001437749-19-023673 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2029-11-25 F1 · derivative.exercise_date: The stock option shall vest and become exercisable in 48 equal monthly installments after November 26, 2019, subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:31 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-Qualified Stock Option (Right to Purchase) · Derivative | 35,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001437749-19-011164 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2029-05-28 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 35,000 non-qualified stock options on May 29, 2019 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 16:34 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 10,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-006480 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,109 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 10,280 shares of common stock on April 1, 2019 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| December 31, 2018 Filed Jan 2, 2019 15:49 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 10,120 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-19-000071 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,829 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 10,120 shares of common stock on December 31, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| October 23, 2018 Filed Oct 25, 2018 12:48 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 17,500 | $0.00 Strike: $3.47 | $0.00 |
DisclosureSEC source: 0001437749-18-018776 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-10-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 17,500 non-qualified stock options on October 23, 2018 (the "Grant Date"). The non-qualified stock options shall vest in full on May 22, 2019. Read SEC document |
| October 01, 2018 Filed Oct 4, 2018 13:17 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 4,285 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-017959 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,709 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 4,285 shares of common stock on October 1, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 18:23 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 4,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-012956 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,424 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 4,040 shares of common stock on July 2, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| May 22, 2018 Filed May 23, 2018 16:20 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 17,500 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001437749-18-010596 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-05-21 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received 17,500 non-qualified stock options on May 22, 2018 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| May 11, 2018 Filed May 15, 2018 19:36 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantStock Options (Right to Purchase) · Derivative | 150,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001437749-18-010052 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2028-05-10 F1 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 150,000 stock options (the "Grant") on May 11, 2018 (the "Grant Date"). The Grant shall vest in equal monthly installments over a period of 24 months following the Grant Date subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| April 02, 2018 Filed Apr 4, 2018 17:43 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 3,089 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-006347 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,384 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 3,089 shares of common stock on April 2, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 21:53 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 2,048 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-18-000289 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,295 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 2,048 shares of common stock on January 2, 2018 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| October 02, 2017 Filed Oct 4, 2017 20:34 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 1,915 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-016825 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,247 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 1,915 shares of common stock on October 2, 2017 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:36 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 17,500 | $0.00 Strike: $5.58 | $0.00 |
DisclosureSEC source: 0001437749-17-015818 · rdgdoc.xml · derivative · entry 2 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2027-09-05 F2 · derivative.exercise_date: The reporting person is a participant in the Issuer's Plan and received 17,500 non-qualified stock options on September 6, 2017 (the "Grant Date"). The non-qualified stock options shall vest in full on the first anniversary of the Grant Date. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 20:36 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 1,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-015818 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,332 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 1,737 shares of common stock on September 6, 2017 (the "Grant Date"). The restricted stock award shall vest in full on the Grant Date. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 19:42 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001209191-17-045601 · doc4.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 15:58 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $1.77 | $0.00 |
DisclosureSEC source: 0000899243-17-017517 · doc4.xml · derivative · entry 2 JORN DEBORA · CIK 0001643304 · EVP, Corp. & Comm'l Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2027-06-27 F3 · derivative.exercise_date: The option to purchase will vest and become exercisable in three equal annual installments beginning June 27, 2018. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 15:58 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantRestricted Stock Units · Derivative | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-017517 · doc4.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · EVP, Corp. & Comm'l Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments beginning June 27, 2018. Vested shares will be delivered to the reporting person within 30 days following each respective vesting date. Read SEC document |
| May 17, 2017 Filed May 19, 2017 20:22 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 686 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-17-009703 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,595 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 686 shares of common stock on May 17, 2017 (the "Grant Date"). The restricted stock award vested in the full on the Grant Date. Read SEC document |
| December 23, 2016 Filed Dec 28, 2016 21:00 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantNon-qualified Stock Option (Right to Purchase) · Derivative | 25,160 | $0.00 Strike: $5.22 | $0.00 |
DisclosureSEC source: 0001437749-16-043878 · rdgdoc.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,160 Underlying: Common Stock · 25,160 shares Expires 2026-12-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan and received 25,160 non-qualified stock options on December 23, 2016 (the "Grant Date"). The non-qualified stock options will vest in equal monthly increments over 48 months following the Grant Date. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 16:03 UTC | VIVEVE MEDICAL, INC. VIVE · Entity 11899 | GrantCommon Stock | 1,109 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-16-042057 · rdgdoc.xml · nonDerivative · entry 1 JORN DEBORA · CIK 0001643304 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,909 F1 · shares: The reporting person is a participant in the Issuer's Amended and Restated 2013 Stock Option and Incentive Plan (the "Plan") and received a restricted stock award of 1,109 shares of common stock on November 9, 2016 (the "Grant Date"). The restricted stock award vested in the full on the Grant Date. Read SEC document |
| November 02, 2016 Filed Nov 4, 2016 14:21 UTC | EyePoint, Inc. PSDV · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0000904454-16-001542 · edgar.xml · derivative · entry 1 JORN DEBORA · CIK 0001643304 · EVP, Corp. & Comm'l Dev. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2026-11-02 F1 · derivative.exercise_date: Options to purchase 75,000 shares shall vest and become exercisable on each of the first, second, third and fourth anniversaries, respectively, of the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.